Clinician Input Template for CADTH pan-Canadian Oncology Drug Review Program

*Before completing this template, be sure to* [*register*](https://drugreviewsadmin.cadth.ca/Landing/Register/Register.aspx?Lang=EN) *with the pCODR program. Please visit* [*www.cadth.ca/pcodr/registration*](http://www.cadth.ca/pcodr/registration) *for information about the registration process.*

1. **About the Registered Clinician**

|  |  |
| --- | --- |
| Name of Registered Clinician |  |
| Title |  |
| Disease Specialty (if applicable) |  |
| Province |  |
| Organization Membership (if applicable, national or provincial) |  |
| Email |  |
| Telephone Number |  |

If this is a joint clinician input submission, please list the names of the other clinicians and disease site specialty (if applicable). Please note that all clinicians listed must also register with CADTH and complete conflict of interest declaration forms.

|  |
| --- |
|  |

**Confirmation of Authorship**

I declare that I am the author of this submission and I confirm that no other parties have written or participated in the writing of the submission, except for those abovenamed in this joint submission (if applicable).

|  |  |  |
| --- | --- | --- |
|  |  |  |
| Signature |  | Date (YYYY/MM/DD) |

1. **About the Drug and Indication Under Review**

|  |  |
| --- | --- |
| CADTH pCODR Project Number | pCODR 10151 |
| Generic Drug Name (Brand Name) | Crizotinib (Xalkori) |
| Indication | LungFirst Line ROS Positive Advanced NSCLC |
| Funding Request | As a single agent as first-line treatment for patients with ROS1-positive advanced non-small cell lung cancer (NSCLC). |
| Trial(s) Being Submitted to pCODRa | [EUROS1 cohort (Mazieres et al, JCO 2015)](https://www.ncbi.nlm.nih.gov/pubmed/25667280)[MA07.05 EUCROSS (Michels et al. JTO 2017)](https://www.jto.org/article/S1556-0864%2816%2931669-0/fulltext)[Wu et al, JCO 2018](https://www.ncbi.nlm.nih.gov/pubmed/29596029) |
| Health Canada Status | 25 August 2017[As monotherapy for use in patients with ROS1-positive locally advanced](https://www.pfizer.ca/sites/g/files/g10037206/f/201711/XALKORI_PM_DC_198322_25Aug2017_E.pdf)[(not amenable to curative therapy) or metastatic NSCLC.](https://www.pfizer.ca/sites/g/files/g10037206/f/201711/XALKORI_PM_DC_198322_25Aug2017_E.pdf) |
| FDA | March 11, 2016[for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive.](https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm490391.htm) |
| European Medicines Agency Status | [21 July 2016](http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/002489/WC500210818.pdf) |
| Practice Guidelinesa | Ellis PM, Vella ET, Ung YC. Systemic treatment for patients with advanced non-small cell lung cancer. [Toronto (ON): Cancer Care Ontario; 2016 November 14. Program in Evidence-Based Care Guideline No.: 7-10 Version 3.](https://www.cancercareontario.ca/en/guidelines-advice/types-of-cancer/31811)Non–Small Cell Lung Cancer, Version 5.2018, NCCN Clinical Practice Guidelines in Oncology. Available from: <https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf> Hanna N, Johnson D, Temin S, et al. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. [J Clin Oncol 2017 35:30, 3484-3515.](http://ascopubs.org/doi/abs/10.1200/JCO.2017.74.6065) |
| Provincial Funding of Current Treatments or Funding Algorithm | The standard of care for patients with ROS-1 mutation positive NSCLC is chemotherapy (e.g., cisplatin plus pemetrexed). Patients could also receive an ALK inhibitor (e.g., crizotinib) or pembrolizumab.  |

a Please note that access to some online publications require subscription.

1. **Key Questions for Clinician Input**

## 3.1 Current Treatment(s) for the Indication Under Review:

* If this is different than what is listed in the Provincial Funding of Current Treatments or Funding Algorithm on the previous page, identify the treatment(s) you would use.
* If more than one treatment is funded in your province, identify the treatment(s) that would be the most appropriate comparator for the drug under review.

|  |
| --- |
|  |

## 3.2 Eligible Patient Population

Describe the patients for whom you would use the new treatment. Examples can include, but are not limited to, the following questions:

* Does the patient population in the reimbursement request align with the need identified in your clinical practice? Is there an unmet need?
* Can the inclusion and exclusion criteria of the clinical trial be applied in clinical practice?
* Is there a subgroup of patients beyond the study population that you would like to use the new treatment in? Is there a subgroup of patients within the study population that the new treatment should be limited to?

|  |
| --- |
|  |

## 3.3 Relevance to Clinical Practice

Do you have experience with using the treatment (through clinical trials, manufacturer’s access program, private drug insurance) under review?

[ ] Yes [ ] No

* How or when would you use the new treatment? Is there any population/subpopulation where you particularly want to use this drug?
* How is the new treatment different than currently available treatments with respect to efficacy, safety, and tolerability?
* Are there contraindications to using the new treatment? Are there contraindications to current treatments that would make the new treatment favourable?

Please note: Scientific published references are not required, as pCODR has access to current scientific literature through the manufacturer’s submission and a rigorous, independent literature search.

|  |
| --- |
|  |

##  3.4 Sequencing and Priority of Treatments

* Please describe how the new treatment could be sequenced with current treatment(s), if appropriate.
* In your opinion, in the event that the drug under review becomes available for funding in your jurisdiction, would the new treatment be a replacement of current treatment(s) or another option?

|  |
| --- |
|  |

## 3.5 Companion Diagnostic Testing

* If companion diagnostic testing is required for the new drug, is the test available in your jurisdiction? Is it funded by your jurisdiction? What concerns, if any, do you have on the test and turnaround time for test results? Are there specific considerations to a testing algorithm that you think would be important to share with the pCODR Expert Review Committee?

|  |
| --- |
|  |

1. **Implementation Questions**

The Ministries of Health and provincial cancer programs across Canada are concerned about the sustainability of high-quality cancer control services. The rising cost of cancer drugs is becoming a major challenge to the sustainability of cancer care funding. While tremendous progress has been made in recent years in the cancer drug system, more is needed to be done to ensure innovative treatments are available to patients, while ensuring value for money for the public.

We are seeking your clinical opinion on the following implementation issues, if and when the new treatment is reimbursed. Your responses would be taken into consideration, among other factors, when Ministries of Health and provincial cancer programs make their final funding decisions.

**4.1.** In regards to question 3.4 above, please consider the optimal sequencing following treatment with crizotinib, specifically: chemotherapy, PD-1 or PD-L1 inhibitors (e.g., nivolumab, pembrolizumab, atezolizumab). In addition, whether the same treatment algorithm for crizotinib in ALK positive patients apply for ROS-1 positive patients.

**4.2.** In clinical practice, how are patients currently being tested for ROS-1 mutations? If crizotinib was reimbursed for patients with ROS-1 mutations in this setting, how would the current practice for the testing for ROS-1 mutations change?

|  |
| --- |
|  |

**4.3.** Please comment on whether ROS-1, EGFR, and ALK mutations are mutually exclusive. Can a patient present with more than one mutation? If yes, which mutation would you treat first?

* + 1. Can a patient develop a mutation to either ALK, EGFR, or ROS-1 over time? If yes, how are these patients clinically managed?

|  |
| --- |
|  |

**4.4.** In clinical practice, can ALK inhibitors be used interchangeably for patients with a ROS-1 mutation? If yes, what is the preferred ALK inhibitor? Please comment on the preference considering patient preference, efficacy, safety, and administration.

|  |
| --- |
|  |

**Appendix A: pCODR Clinician Conflict of Interest Declarations**

**Please note: Each registered clinician must complete their own separate pCODR Clinician Conflict of Interest Declarations Template even if the submission is made jointly.**

|  |  |
| --- | --- |
| **Name of registered clinician:** |  |
| **Name of drug and indication under review:** |  |

**Conflict of Interest Declaration**

To maintain the objectivity and credibility of the pCODR process, all participants in the pCODR review process must disclose any conflicts of interest. A registered clinician must declare any potential conflicts of interest that may influence or have the appearance of influencing the information submitted. A conflict of interest declaration is requested for transparency — it does not negate or preclude the use of the clinician input.

Examples of conflicts of interest include, but are not limited to:

* financial support from the pharmaceutical industry or other entities (e.g., educational or research grants, honoraria, gifts, and salary)
* affiliations, or personal or commercial relationships with drug manufacturers or other interest groups.

**Section A: Payment Received**

1. Have you received any payments over the previous two years from any company or organization that may have a direct or indirect interest in the drug under review?

|  |
| --- |
|[ ]  Yes |
|[ ]  No |

 If no, please go to Section B.

1. What form of payment did you receive? (Check all that apply.)

|  |  |  |
| --- | --- | --- |
|[ ]  Advisory role (e.g., advisory boards, health technology assessment submission advice)  |[ ]  Program or Operating Funding (e.g., website)  |  |
|[ ]  Conference attendance  |[ ]  Research/educational grants  |  |
|[ ]  Royalties |[ ]  Travel grants |  |
|[ ]  Gifts  |[ ]  Sponsorship of events |  |
|[ ]  Honoraria |[ ]  Other, please specify:  |  |

1. Please provide the names of companies and organizations, and the amounts of the payments, in the following box.

|  |
| --- |
|  |

**Section B: Holdings or Other Interests**

Have you received or are in possession of stocks or options of more than $10,000 (excluding mutual funds) for organizations that may have a direct or indirect interest in the drug under review? If yes, please list them in the following box.

|  |
| --- |
|  |

**Section C: Affiliations, Personal or Commercial Relationships**

Do you have personal or commercial relationships either with a drug or health technology manufacturer (including the manufacturer’s parent corporation, subsidiaries, affiliates, and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations, and outline the nature of these relationships, in the following box.

|  |
| --- |
|  |

I hereby certify that I have disclosed all relevant information with respect to any matter involving a Party that may place me in a real, potential, or perceived conflict of interest situation.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  |  |  |  |  |
| Date |  | Name |  | Signature |